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Abstract
Background: Despite a high mortality rate in childhood, there is limited evidence on the causes and outcomes of
paediatric bloodstream infections from low- and middle-income countries (LMICs). We conducted a systematic
review and meta-analysis to characterize the bacterial causes of paediatric bloodstream infections in LMICs and
their resistance profile.
Methods: We searched Pubmed and Embase databases between January 1st 1990 and October 30th 2019,
combining MeSH and free-text terms for “sepsis” and “low-middle-income countries” in children. Two reviewers
screened articles and performed data extraction to identify studies investigating children (1 month-18 years), with at
least one blood culture. The main outcomes of interests were the rate of positive blood cultures, the distribution of
bacterial pathogens, the resistance patterns and the case-fatality rate. The proportions obtained from each study
were pooled using the Freeman-Tukey double arcsine transformation, and a random-effect meta-analysis model
was used.
Results: We identified 2403 eligible studies, 17 were included in the final review including 52,915 children (11 in
Africa and 6 in Asia). The overall percentage of positive blood culture was 19.1% [95% CI: 12.0–27.5%]; 15.5% [8.4–
24.4%] in Africa and 28.0% [13.2–45.8%] in Asia. A total of 4836 bacterial isolates were included in the studies; 2974
were Gram-negative (63.9% [52.2–74.9]) and 1858 were Gram-positive (35.8% [24.9–47.5]). In Asia, Salmonella typhi
(26.2%) was the most commonly isolated pathogen, followed by Staphylococcus aureus (7.7%) whereas in Africa,
S. aureus (17.8%) and Streptococcus pneumoniae (16.8%) were predominant followed by Escherichia coli (10.7%).
S. aureus was more likely resistant to methicillin in Africa (29.5% vs. 7.9%), whereas E. coli was more frequently resistant
to third-generation cephalosporins (31.2% vs. 21.2%), amikacin (29.6% vs. 0%) and ciprofloxacin (36.7% vs. 0%) in Asia.
The overall estimate for case-fatality rate among 8 studies was 12.7% [6.6–20.2%]. Underlying conditions, such as
malnutrition or HIV infection were assessed as a factor associated with bacteraemia in 4 studies each.
Conclusions: We observed a marked variation in pathogen distribution and their resistance profiles between Asia and
Africa. Very limited data is available on underlying risk factors for bacteraemia, patterns of treatment of multidrug-
resistant infections and predictors of adverse outcomes.
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Background
Estimated global childhood mortality has declined from
9.5 million to 7 million deaths annually over the past
decade. This is largely due to the reduction of mortality
in certain high-burden infectious diseases including diar-
rhea, pneumonia, malaria and measles [1]. However,
sepsis remains the second leading cause of death with an
estimated mortality rate of 7% in the paediatric popula-
tion [2]. Most of these deaths were reported from facil-
ities in Sub-Saharan Africa and Asia, where healthcare
access, infrastructure and staffing remains sub-optimal.
Bacterial infections, such as lower respiratory tract infec-
tion, meningitis and other infectious diseases, remain
the leading causes of death in these regions [3]. Of note,
epidemiology of bacterial infections is different across
the world: studies of children with bacteraemia in Africa
suggest that prevalence of bacterial infections among in-
patients with bacteraemia is greater than that described
in wealthier regions [4–6].
In resource-limited settings, the emerging threat of multi-
drug resistance among Gram-negative bacteria (GNB) is a
major concern, given the scarcity of diagnostic microbiology
laboratories and difficulty in accessing effective antibiotic
therapy for resistant pathogens. Rising antibiotic resistance
rates among E. coli (with resistance to third-generation
cephalosporins and fluoroquinolones) is particularly prob-
lematic, since cephalosporins are the mainstay of empiric
therapy for both community-acquired and hospital-acquired
bloodstream infection in resource-limited settings.
The estimated prevalence of extended-spectrum beta-
lactamase (ESBL)-producing Enterobacteriaceae in Asia and
Sub-Saharan Africa is between 60 and 90% [7], highlighting
the growing challenge of treating bloodstream infections in
these countries. In May 2017, the United Nations World
Health Assembly and World Health Organization (WHO)
approved a resolution to tackle sepsis and made it a global
health priority in the next decade [8].
The current WHO guideline recommends the combin-
ation of ampicillin and gentamicin for empiric treatment
of paediatric sepsis. The second-line antibiotic recom-
mended is a third-generation cephalosporin, or when
staphylococcal infection is suspected, flucloxacillin and
gentamicin should be considered [9]. Despite the above
recommendations, many low- and middle-income coun-
tries (LMIC) utilize third-generation cephalosporins as
first-line treatment for severe sepsis owing to their
affordability and widespread availability [10].
Only very limited data on the etiology, epidemiology
and antimicrobial susceptibility of the key pathogens are
available regarding paediatric bacteraemia in low- and
middle-income countries (LMIC) [11]. Given the paucity
of epidemiological data on bacteraemia in children, we
undertook a systematic review and meta-analysis, char-
acterizing community-acquired paediatric bacteraemia
in LMIC settings, including identification of key patho-
gens and antimicrobial resistance patterns.
Methods
Search strategy and selection criteria
Studies were considered eligible for inclusion if they re-
ported children with community-acquired bloodstream
infections, as defined by authors, which were laboratory-
confirmed with a positive blood culture, from low and
middle-income countries. Furthermore, studies had to in-
clude (i) infants or children aged > 1month but less than
18 years of age; (ii) infants/children with submission of at
least one aerobic blood culture; and (iii) data reporting the
total number of pathogenic bacteria isolated. Countries
were classified based on income using World Bank
categories [12].
Pubmed and Embase databases were systematically
searched for studies reported between January 1st 1990
and October 30th 2019. Pubmed was searched with a
strategy combining MeSH (Medical Subject Headings)
and free text: (sepsis OR bacterem* OR bacterae* OR
septicaem* OR septicem* OR fever OR “bloodstream in-
fection”) AND (“developing countri*” OR “under-devel-
oped nations” OR “third-world countr*” OR “third-world
nation” OR “Resource-limited setting” OR “low-middle-
income countr*” OR “low-income countr*” OR “middle-
income countr*”). The detailed search strategy used in
Embase is described in Additional file 1. Search strategy
was restricted to English language. The study protocol
was registered in PROSPERO (International prospective
register of systematic reviews) under number 100367.
Two reviewers (ND, RB) performed the electronic
searches and screened the titles and abstracts, independ-
ently. Studies that did not meet eligibility criteria were
rejected on initial review. Articles marked for potential
inclusion were obtained electronically or in paper copy
and assessed again for inclusion. Any disagreements over
the eligibility of particular studies were resolved through
discussion with a third reviewer (MS).
We excluded studies that reported only hospital ac-
quired infections, only assessed bloodstream infection in
specific risk group (e.g. neutropenia, sickle cell anaemia),
investigated a specific clinical syndrome (e.g. pneumonia,
meningitis), or studies that were not from LMIC. We
also excluded systematic reviews, case reports, editorials,
policy statements, and studies during epidemic or out-
break. As we aimed to focus only on paediatric sepsis,
we excluded studies where data on pathogen distribution
and antibiotic resistance patterns were pooled i.e. not
distinguishable between neonates, infants, older children,
adolescents and adults. We excluded studies that focused
on neonates since the epidemiology of neonatal infections
is different to that of older children. Moreover, a review of
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community-acquired pathogens in neonatal sepsis in Asia
and Africa has already been published [13].
Finally, we excluded studies that included only fungal
infections or studies that included culture sites other
than blood, where the results could not be separated by
site of specimen.
Quality assessment
To score the quality of eligible publications, we used the
STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE) Statement on items that should
be included in reports of cohort studies [14]. We calcu-
lated the proportion of items of the STROBE checklist
adequately reported for each study. We did not exclude
any studies based on quality.
Data extraction
Descriptive and quantitative data from each included paper
were extracted individually by two reviewers (ND and RB).
Information for extractions included: hospital setting, coun-
try and region of the study, years the study was carried out,
study period, inclusion criteria used in each study, blood
cultures techniques, age range, number of patients who had
blood cultures sampled, the number who had positive cul-
tures for a bacterial pathogen, pathogens and contaminants
isolated, and when available: mortality rate, co-infection
with malaria at BSI diagnosis, prevalence of malnutrition,
HIV status, and antimicrobial susceptibilities.
Data on blood culture contamination rate and most
prevalent blood culture contaminants was not provided
in almost all included papers and we were unable to in-
clude this factor in the final analysis.
Statistical analysis
We performed a meta-analysis to estimate the rate of
bacteraemia, the proportional representation of each
pathogen and the case-fatality rate. A random-effect
meta-analysis model was used to control for the inter-
study variability effect. The proportions obtained from
each study were pooled using the Freeman-Tukey double
arcsine transformation and generated forest plots [15]. A
p value < 0.05 was considered to be statistically significant.
I2 statistic was used to determine heterogeneity [16]. Low,
moderate, and high heterogeneity was defined to levels of
I2 values of 25, 50, and 75% respectively [16]. We also per-
formed a subgroup meta-analysis for each pathogen and
by continent. All statistical tests were performed with R
statistical package 3.3.2 (R Foundation for Statistical
Computing, Vienne, Austria).
Results
Study selection and description
We identified 2403 potentially relevant studies through
the database search. Of these, there were 107 duplicates
and 2195 were excluded on basis of title and abstract
screening. A total of 17 studies [17–33] were included in
the final review (Fig. 1); they were conducted in 12 coun-
tries (6 in Africa and 6 in Asia) between 1988 and 2011
and published between 1992 and 2016 (Additional file 1:
Tables S1a and S1b). No studies from regions other than
Africa and Asia, or any studies conducted after 2011 were
eligible based on these inclusion criteria.
Quality assessment
Overall, the published studies reported on a median of
66% (range 50–81%) of STROBE items (Additional file 1:
Tables S1a and S1b).
Study designs
All studies included were observational cohort studies,
16 were prospective [17–31, 33] and 1 was retrospective
[32]. The median duration of the study period was 32
months (IQR 12–48).
Two studies [22, 25] investigated the etiology of posi-
tive blood cultures in all child admissions (11.8%), 11
[17–21, 23, 26–28, 30, 33] only in children admitted
with fever without localizing features (64.7%) and 4
[24, 29, 31, 32] studies reported bloodstream infec-
tions in children admitted with signs of severe illness
or suspected sepsis (23%).
Five studies [18, 23, 25, 31, 32] specifically defined
community-acquired bacteraemia as clinically relevant
positive blood cultures taken within 48 h of hospital ad-
mission or if blood culture was taken after 48 h and the
clinical presentation and identified pathogen were con-
sistent with community-acquired disease. Eleven other
studies [13, 15–18, 20, 22, 24–26, 29] reported
community-acquired bacteraemia exclusively, but did
not give a clear definition of community-acquired blood-
stream infection. One study [27] reported both community-
acquired (90%) and hospital-acquired (10%) infections.
Ten studies (58.8%) [18–20, 22, 25, 26, 28–31] reported
the volume of blood specimens sampled from patients. The
culture media and methods of identification of organisms
varied between studies with minimum culture volumes ran-
ging from 1mL to 5mL. Ten studies (58.8%) reported the
antimicrobial susceptibility method was applied: disc diffu-
sion method only [18, 21, 28–30, 32, 33], or disc diffusion
method and Etest (Epsilometer test) [25, 26, 31]. Five of
them described guidelines they used to check laboratory
quality (3 in accordance to the Clinical Laboratory Stan-
dards Institute [25, 26, 32] and 2 in accordance to the ex-
ternal quality assurance program of the United Kingdom
National External Quality Assessment Service [23, 33]).
Demographics
A total of 61,015 children were included in the initial re-
view. Of these, 9818 children were from Asian countries
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(16.1%) and 51,197 from African countries (83.9%). Dur-
ing the data extraction, we excluded 8100 patients as
their ages were less than 1 month or more than 18 years.
Finally, 52,915 children aged between 1month and 18
years were included in the systematic review. Among
these children, 44,859 (84.8%) were from rural district
hospitals, and 8056 (15.2%) from urban hospitals and re-
ferral centres. The overall rate of positive blood culture
was 19.1% [95% confidence interval (CI): 12.0–27.5; I2 =
99.8%], with 15.5% [95% CI: 8.4–24.4; I2 = 99.8%] in
Africa and 28.0% [95%CI: 13.2–45.8; I2 = 99.3%] in Asia
(Fig. 2). The majority of included studies did not report
any data on comorbidities.
Nutrition status was reported in only four studies
[18, 22, 25, 33]. Severe malnutrition was significantly
associated with bacteraemia in two of them with an
odds ratio of 2.02 (95% CI 1.65 to 2.47) [22] and
1.82 (95% 1.60 to 2.08) [21]. In contrast, no associ-
ation was found between bacteraemia and malnutri-
tion in the 2 other studies [18, 33].
Fig. 1 Diagram for study selection
Droz et al. Antimicrobial Resistance and Infection Control           (2019) 8:207 Page 4 of 12
Only 4 studies [18, 22, 26, 33] included HIV anti-
body testing and reported the results, of which two
studies described an association between HIV infec-
tion and bacteraemia with an odds ratio of 3.22
(95% CI: 2.34–4.44) [22] and 2.68(95% CI: 1.55 to
4.64) [18].
Similarly, the prevalence of concurrent malaria was
poorly described: four studies [17, 20, 25, 33] reported
prevalence of malaria parasitaemia with species unspecified.
Eight studies [18, 19, 22, 23, 25–28] reported the all-
cause fatality rate amongst patients with a bloodstream
infection. The overall estimate for all-case fatality rate
was 12.7% [95%CI: 6.6–20.2; I2 = 96.2%] (Fig. 3).
Sources of infection
Only 3 studies reported the suspected underlying source
of infection [24, 27, 33]. Of these studies, pneumonia was
reported as the first source of infection in 2 studies (32
and 43%) [24, 33]. In 1 study [27], the focal source of bac-
teraemia were gastroenteritis (40.4%), pneumonia (20%),
meningitis (7.4%) and urinary tract infections (7.4%).
Bacterial identification
A total of 4836 bacterial isolates were included in the
studies. Of these, 2974 were Gram-negative (63.9%
[52.2–74.9]; I2 = 98.5%) (Fig. 4) and 1858 were Gram-
positive (35.8% [24.9–47.5]; I2 = 98.4%) (Additional file 2:
Figure S1). Four pathogens were classified as other
species. The most commonly isolated pathogens were
S. aureus, S. pneumoniae, E. coli, non-typhoidal Salmonella
and S. typhi (Table 1).
Gram-negative bacteria predominance was higher in
Asia (79.0% [56.7–94.8]; I2 = 98.3%) than in Africa
(54.8% [45.1–64.4]; I2 = 96.8%]. In Asia, Salmonella typhi
(26.2% [0.75–68.47]; I2 = 99.5%) ranked first followed by
S. aureus (7.7% [3.3–13.6]; I2 = 89%), Klebsiella sp. (6.6%
[0.8–16.6]; I2 = 96.1%), S. pneumoniae (6.3% [0.3–17.9];
I2 = 97.1%), and E. coli (5.5% [2.4–9.7]; I2 = 83.1%),
whereas in Africa, S. aureus (17.8% [8.7–29.2]; I2 =
98.3%) and S. pneumoniae (16.8% [8.5–27.3]; I2 = 98.1%)
were predominant followed by E. coli (10.7% [5.8–16.1];
I2 = 95.9%) and non-typhoidal Salmonella (9.8% [3.1–
19.4]; I2 = 98.4%) (Table 1). No significant trends on the
variation of the proportion of the main pathogens in
Fig. 2 Proportion of bacteraemia in the included studies
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both continents were observed by year of publication
(data not shown).
Pathogens thought to be contaminants were explicitly
reported to have been excluded from the analyses in 8
studies [18, 20, 22, 23, 25, 26, 32, 33]. In 6 studies
[17, 21, 27, 29–31] providing full data, contaminants
were isolated from 132 (2%) blood cultures. These
included 111 Staphylococcus epidermidis, 16 Strepto-
coccus viridans, and 4 Bacillus cereus.
Antibiotic susceptibility testing
We obtained antimicrobial susceptibility data from 6
studies in Africa [18, 21, 23, 25, 26, 33] and 5 studies
from Asia [28–32] that reported detailed antimicrobial
susceptibility test (AST) results, including a total of 3078
isolates (2194 isolates in Africa and 884 isolates in Asia).
Overall, we observed antimicrobial resistance rates of
59.7% (1988/3328) to ampicillin, 33.5% (769/2295) to
gentamicin, 34.9% (287/822) to amikacin, 45.3% (1518/
3348) to chloramphenicol, 49.0% (1371/2800) to cotri-
moxazole, 33.9% (496/1464) to third-generation cephalo-
sporins, and 43.3% (385/890) to ciprofloxacin. Table 2
shows the number of isolates of the major pathogens
that were susceptible to the main antibiotics. We ob-
served that S. aureus was more likely to be resistant to
methicillin (oxacillin, third-generation cephalosporins)
in Africa than in Asia (29.5% vs. 7.9%, respectively) as
well as to cotrimoxazole (49.7% vs. 20.3%, respectively).
S. pneumoniae exhibited high susceptibility to beta-
lactams in Africa, whereas 22% of isolates were resistant
to ampicillin in Asia (Table 2). E. coli and Klebsiella sp.
were more frequently resistant to the 3rd generation
cephalosporins, aminoglycosides, and ciprofloxacin in
Asia than in Africa (Table 2). In Asia, about one third of
S. typhi isolates were resistant to first-line antibiotics
(33.3% to ampicillin, 32.7% to chloramphenicol and 16%
to cotrimoxazole), 7% to third-generation cephalospo-
rins, and 14% to ciprofloxacin (26% revealed resistance
to nalidixic acid) (Table 2). It was not possible to iden-
tify trends in resistance rates over time, due to the lack
of standard reporting between studies.
Discussion
To our knowledge, this is the largest systematic review
that has characterized the pathogen distribution and anti-
microbial resistance patterns in paediatric bacteraemia in
LMICs including 52,915 children and 4836 isolates. We
identified a high rate of positive blood cultures (19.1%),
while previous studies have observed a percentage of posi-
tive blood culture from 7 to 13.9% [7, 34]. Gram-negative
bacteria accounted for 63.9% of all episodes, and Salmon-
ella spp. was the most common pathogen reported in Asia
Fig. 3 All-cause mortality rate in the included studies
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(31.1%). S. aureus and S. pneumoniae were more predom-
inant in Africa.
There was a high overall antimicrobial resistance rate
to the first-lines drugs (ampicillin and gentamicin) but
also to the second line recommended therapy (3rd
generation cephalosporins and amikacin).
Of interest, we observed a marked variation of resistance
patterns between Asia and Africa. Indeed, S. aureus was
more commonly resistant to methicillin in Africa, whereas
E. coli was more frequently resistant to 3rd generation
cephalosporins, amikacin and ciprofloxacin in Asia.
Overall, these results are consistent with a previous sys-
tematic review in which Gram-negative bacteria accounted
for 66.8% of sepsis cases in resource-limited countries, with
Salmonella spp. as predominant cause of sepsis in Asia [7];
whereas Gram-positive pathogens were more likely in-
volved in high-income countries [35]. The high levels
of resistance we observed are similar to those pre-
viously described in Sub-Saharan Africa and Asia.
Indeed, in a recent systematic review [10], prevalence
of bacteria susceptible to the penicillin and gentamicin
combination, to chloramphenicol, and to third gener-
ation cephalosporins was 63, 47 and 64%, respectively
among older infants with bacteraemia.
The overall all-cause mortality rate in this review was
12.7% [6.6–20.2]. Although difference in mortality due
to sepsis is most likely related to the higher prevalence
of comorbidities such as malaria, malnutrition, or im-
munosuppression [36], we found very few studies that
included HIV-infected children [18, 22, 33] despite the
fact that HIV infection is the most common cause of
morbidity and mortality in children in sub-Saharan Africa
[18]. Data on all the comorbidities associated with bacter-
aemia are scarce in the studies; it is difficult to draw
conclusions.
Moreover, no information was available about other
factors that may contribute to risk of mortality from
bacteraemia, including access to health care, vaccination
status, late clinical diagnosis, concordant versus discord-
ant empiric treatment, time to first dose of antibiotics
and time to switch from empiric to targeted therapy. In-
deed, for optimal outcomes, treatment of sepsis is time
sensitive and should be started before laboratory data
confirm the diagnosis [37]. Moreover, in a study from
Thailand conducted in 2010, it was estimated that around
an extra 19,000 deaths were caused by multi-drug resist-
ant bacteria each year [38] . The mortality attributable to
ESBL-producing pathogens and methicillin-resistant S.
Fig. 4 Proportion of Gram-negative bacteria (GNB) in paediatric bacteraemia
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aureus (MRSA) is estimated to be 27 and 34% in neonatal
sepsis in Tanzania, respectively [39], which has been used
to estimate that 58,319 deaths could be attributable to
ESBL and MRSA in India alone [40].
Strength and limitations
To the best of our knowledge, this is the largest system-
atic review to date describing the pathogen distribution
and AMR patterns amongst children with bacteraemia
across LMIC settings. However, there are several limita-
tions to be addressed. First, this review includes only 17
studies combining data from 4706 episodes of bacter-
aemia from 12 countries, representing 9% (12/137) of
the LMIC defined in The World Bank classification [12].
The estimated rates of bacteraemia and all-cause mortal-
ity as well as pathogen distribution and AMR patterns
are therefore not representative of the entire region.
Secondly, we observed high heterogeneity between
studies that may be ascribed to the heterogeneity of the
study designs but also the timeframe as studies spanned
a period of more than 20 years, so inclusion criteria,
hospital type, population characteristics varied consider-
ably, which raises concerns about the appropriateness of
our aggregation of the different datasets. However, we
attempted to control heterogeneity by specifying prede-
fined inclusion criteria and by using a random-effect
meta-analysis model. We further performed subgroup
analyses by continents (Asia and Africa) to explore the
effect of heterogeneity on the overall prevalence of
bloodstream infections and for each pathogen. Unfortu-
nately, we did not observe a decrease of the heterogen-
eity by subgroup analyses. Concerningly only limited
recent data could be identified, since the most recent
study we included was published in 2016 on data col-
lected between 2001 and 2011 [32]. Our strict inclusion
criteria may have led to exclusion of papers in which the
distribution of pathogens could not be distinguished
from neonates to older children. Similarly, South Ameri-
can studies were either missed by the search strategy or
did not contain any data met the study inclusion criteria.
In addition, as we did not use concrete names of coun-
tries, some other studies from LMIC that did not use
LMIC or similar terms may have been missed by the
search strategy.
Thirdly, the search strategy was made with two major
scientific databases and included only English-language
literature. These two points may have led to selection
bias since the articles of interest may not have been
published in English or in these two databases.
Fourthly, the quality assurance practices of clinical
microbiology labs, particularly in rural lab settings of
low income countries, are likely not of equal proficiency
and the identification and particularly the susceptibility
testing results may be different between studies. For
example, reporting aminoglycosides susceptibility for
Salmonella species in 6 studies [18, 25, 26, 28, 29, 33] is
concerning (these agents are not considered clinically
useful against Salmonella species). Although WHO [41]
recommends laboratory results as accurate as possible,
with all aspects of the laboratory operations must be re-
liable, in our study, only five studies described guidelines
they used to check laboratory quality [23, 25, 26, 32, 33].
Then, denominators for every organism differ across
the tested antibiotics (i.e., 446 S. aureus were tested to
ampicillin, 600 to gentamicin and only 172 to cephalo-
sporins), that may suggest heterogeneity between labora-
tory practices. However, given the extremely limited
data available, we chose to rather include these studies
in our review, but to acknowledge the above mentioned
limitations. Quality in reporting practices are also im-
portant in order to be useful in a clinical or public health
setting. The challenge is to reduce the level of inaccur-
acy as much as possible, given the limitations of our
testing systems.
Fifthly, our review revealed a very high resistance of
Klebsiella sp. in Asia, which should be interpreted with
caution because 96% of Klebsiella sp. bacteraemia epi-
sodes included in this review were retrieved from one
single study based in India [29]. A previous study re-
ported that India had the highest rates of paediatric
ESBL rates in Asia [42]. A retrospective analysis of neo-
natal Gram-negative septicemia from 2002 to 2003
reported that 61% (46/75) of cases were due to ESBL-
producing strains [43].
Conclusions
As defined by the World Health Assembly in 2017
[44], improving the understanding of the epidemio-
logical and financial burden of sepsis worldwide is a
priority. In our review, we focused on description of
paediatric bacteraemia and and we identified a major
lack of recent high quality data from LMIC settings.
There is a clear need for new prospective studies of
paediatric community-acquired sepsis that utilize stan-
dardized definitions. These future studies should de-
scribe the clinical presentation, identify the infection
source, document underlying co-morbidities and fac-
tors associated with mortality of children presenting
with bacteremia.
Similarly, recent data on the antimicrobial resist-
ance patterns are essential to accurately evaluate the
appropriateness of currently-recommended empiric
and targeted antibiotic therapies. Our results suggest
that new empiric treatment regimens and strategies
for enhanced prevention of paediatric bacteraemia
and other serious bacterial infections are needed to
reduce attributable child mortality.
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